Subodh Verma




Please note: Dr. Verma will not take students in summer.

Dr. Subodh Verma is an internationally renowned cardiac surgeon-scientist and Professor at the University of Toronto. He is the current Canada Research Chair in Cardiovascular Surgery, having previously served as the Canada Research Chair in Atherosclerosis (2007-2017). Dr. Verma was recently awarded the 2021 Lister Prize in Surgery from the University of Toronto in recognition of his outstanding and continuing productivity of international stature. He is a past recipient of the Howard Morgan Award for Distinguished Achievements in Cardiovascular Research and the Royal College of Physicians and Surgeons of Canada Gold Medal in Surgery. He is an appointee of the American Association of Thoracic Surgeons (AATS) and a member of the College of New Scholars, Artists and Scientists, Royal Society of Canada. According to Google Scholar in April 2021, Dr. Verma has an h-index of 100 and his work has been cited over 50,000 times.

Dr. Verma has published extensively in highly impactful journals like the NEJM, Lancet, Circulation, JACC, Nature, and JCI. He is an Associate Editor of the European Heart Journal. Dr. Verma is an active contributor to Canadian clinical practice guidelines and co-authored the recently updated recommendations for atrial fibrillation, antiplatelet therapy, diabetes, and heart failure; he was a member of the 2018 AATS consensus guidelines committee on bicuspid aortic valve-related aortopathy. Dr. Verma has served in various capacities on the American Heart Association Council on Cardiovascular Surgery and Anesthesia since 2008.

Dr. Verma had/has leadership roles on 10 contemporary global heart failure trials – several of which have let to paradigm changes in how individuals all around the world who live with diabetes and heart failure are now managed. He founded and oversees the CardioLink platform at St Michael’s Hospital that is conducting cardiometabolic and surgically oriented RCTs and translational studies.

Dr. Verma leads a dynamic pre-clinical and translational research team that leverages pre-clinical disease models and clinical trial-derived data to identify novel mediators of cardiovascular and cardiometabolic disease as well as answer timely and relevant healthcare questions. His research has yielded 2 United States patents and is supported by several national peer-reviewed grants.


Recent Publications

  1. Böhm, M, Butler, J, Krawczyk, M, Mahfoud, F, Haring, B, Filippatos, G et al.. Liver tests, cardiovascular outcomes and effects of empagliflozin in patients with heart failure and preserved ejection fraction: the EMPEROR-Preserved Trial. Eur J Heart Fail. 2023; :. doi: 10.1002/ejhf.2922. PubMed PMID:37278451 .
  2. Puar, P, Ahmed, S, Hibino, M, Pasricha, A, Pandey, A, Bari, A et al.. The association between anthropometric indicators of obesity and cardiac reverse remodelling with empagliflozin in patients with type 2 diabetes and coronary artery disease. Diabetes Obes Metab. 2023; :. doi: 10.1111/dom.15119. PubMed PMID:37246798 .
  3. Khan, MS, Segar, MW, Usman, MS, Patel, KV, Van Spall, HGC, DeVore, AD et al.. Effect of Canagliflozin on Heart Failure Hospitalization in Diabetes According to Baseline Heart Failure Risk. JACC Heart Fail. 2023; :. doi: 10.1016/j.jchf.2023.03.025. PubMed PMID:37227388 .
  4. Butler, J, Usman, MS, Filippatos, G, Ferreira, JP, Böhm, M, Brueckmann, M et al.. Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction: A Post Hoc Analysis of the EMPEROR-Preserved Trial. JAMA Cardiol. 2023; :. doi: 10.1001/jamacardio.2023.1090. PubMed PMID:37223933 PubMed Central PMC10209829.
  5. Hibino, M, Pandey, AK, Hibino, H, Verma, R, Aune, D, Yanagawa, B et al.. Mortality trends of aortic stenosis in high-income countries from 2000 to 2020. Heart. 2023; :. doi: 10.1136/heartjnl-2023-322397. PubMed PMID:37208159 .
  6. Verma, S, Dhingra, NK, Bonaca, MP, Butler, J, Anker, SD, Ferreira, JP et al.. Presence of Peripheral Artery Disease Is Associated With Increased Risk of Heart Failure Events: Insights From EMPEROR-Pooled. Arterioscler Thromb Vasc Biol. 2023; :. doi: 10.1161/ATVBAHA.123.319156. PubMed PMID:37199158 .
  7. Butler, J, Packer, M, Siddiqi, TJ, Böhm, M, Brueckmann, M, Januzzi, JL et al.. Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories. J Am Coll Cardiol. 2023;81 (19):1902-1914. doi: 10.1016/j.jacc.2023.03.390. PubMed PMID:37164523 .
  8. Hibino, M, Verma, S, Pandey, AK, Bisleri, G, Yanagawa, B, Verma, R et al.. The Impact of Statins on Postdischarge Atrial Fibrillation After Cardiac Surgery: Secondary Analysis from a Randomized Trial. CJC Open. 2023;5 (4):285-291. doi: 10.1016/j.cjco.2022.12.012. PubMed PMID:37124963 PubMed Central PMC10140742.
  9. Verma, S, Husain, M, Madsen, CM, Leiter, LA, Kuhlman, AB, Vilsbøll, T et al.. Neutrophil to lymphocyte ratio predicts cardiovascular events in people with type 2 diabetes: Post hoc analysis of the SUSTAIN 6 and PIONEER 6 cardiovascular outcomes trials. Diabetes Obes Metab. 2023; :. doi: 10.1111/dom.15088. PubMed PMID:37046366 .
  10. Puar, P, Mistry, N, Connelly, KA, Yan, AT, Quan, A, Teoh, H et al.. IGFBP7 and left ventricular mass regression: a sub-analysis of the EMPA-HEART CardioLink-6 randomized clinical trial. ESC Heart Fail. 2023;10 (3):2113-2119. doi: 10.1002/ehf2.14335. PubMed PMID:37038626 PubMed Central PMC10192263.
Search PubMed

Affiliations & Other Activities

  • Cardiac Surgeon, Division of Cardiology , St. Michael’s Hospital
  • Professor of Surgery and Pharmacology & Toxicology, University of Toronto
  • Canada Research Chair in Cardiovascular Surgery